







an Open Access Journal by MDPI

## Vaccines and Vaccinations in the Pandemic Period

Guest Editors:

### **Dr. Dimitrios Papagiannis**

Assistant Professor of Public Health, Public Health & Vaccines Lab., Faculty of Nursing, School of Health Sciences, University of Thessaly, Gaiopolis Campus, Larissa, Greece

# **Dr. Georgios Rachiotis**

Department of Hygiene and Epidemiology, **M**edical Faculty, University of Thessaly, 41222 Larissa, Greece

Deadline for manuscript submissions:

15 December 2024

# **Message from the Guest Editors**

In this Special Issue, original research articles and different types of evidence-summaries are welcome. Research areas may include (but not limited to) the following:

- 1. Public health and policy issues, including vaccination coverage, vaccine research, communication strategies for encouraging vaccine uptake, vaccines hesitancy.
- Surveillance of COVID-19 vaccines, including efficacy and effectiveness of vaccines in the context of new variants, novel vaccine platforms, safety, booster doses
- 3. Routine vaccinations in work places, infant's and adults in Pandemic period..







IMPACT FACTOR 7.8





an Open Access Journal by MDPI

## **Editor-in-Chief**

#### Prof. Dr. Ralph A. Tripp

Department of Infectious Diseases, College of Veterinary Medicine, University of Georgia, Athens, GA 30602-7387, USA

# **Message from the Editor-in-Chief**

Vaccines (ISSN 2076-393X) has had a 6-year history of publishing peer-reviewed state of the art research that advances the knowledge of immunology in human disease protection. Immunotherapeutics, prophylactic vaccines, immunomodulators, adjuvants and the global differences in regulatory affairs are some of the highlights of the research published that have shaped global health. Our open access policy allows all researchers and interested parties to immediately scrutinize the rigorous evidence our publications have to offer. We are proud to present the work and perspectives of many to contribute to future decisions concerning human health.

#### **Author Benefits**

**Open Access:** free for readers, with <u>article processing charges (APC)</u> paid by authors or their institutions.

**High Visibility:** indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Immunology) / CiteScore - Q1 (Pharmacology (medical))

#### **Contact Us**